Rapid in vivo assessment of drug efficacy against mycobacterium tuberculosis using an improved firefly luciferase

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2118-2127

  Andreu, Nuria ^a,b   Zelmer, Andrea ^b   Sampson, Samantha L ^a   Ikeh, Melanie ^a,e   Bancroft, Gregory J ^b   Schaible, Ulrich E ^b,c   Wiles, Siouxsie ^d   Robertson, Brian D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c RESEARCH CENTER BORSTEL   (Germany)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Bioluminescence; Drug testing; Mouse model; Optical imaging

Indexed keywords

FIREFLY LUCIFERASE; ISONIAZID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BIOLUMINESCENCE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EX VIVO STUDY; FEMALE; IN VIVO STUDY; LUMINESCENCE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; TREATMENT DURATION; TUBERCULOSIS;

BIOLUMINESCENCE; DRUG TESTING; MOUSE MODEL; OPTICAL IMAGING;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GENES, REPORTER; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MICE; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS; WHOLE BODY IMAGING;

EID: 84882647138     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt155     Document Type: Article

References (27)

1. WHO. Tuberculosis Fact Sheet. http://www.who.int/mediacentre/factsheets/fs104/en/index.html (10 April 2013, date last accessed).
2. Andreu N, Zelmer A, Wiles S. Noninvasive biophotonic imaging for studies of infectious disease. FEMS Microbiol Rev 2011; 35: 360-94.
3. Rice BW, Cable MD, Nelson MB. In vivo imaging of light-emitting probes. J Biomed Opt 2001; 6: 432-40.
4. Zhao H, Doyle TC, Coquoz O et al. Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt 2005; 10: 41210.
5. Prioli RP, Tanna A, Brown IN. Rapid methods for counting mycobacteria-comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Tubercle 1985; 66: 99-108.
6. Janaszek W, Aleksandrowicz J, Sitkiewicz D. The use of the firefly bioluminescent reaction for the rapid detection and counting of Mycobacterium BCG. J Biol Stand 1987; 15: 11-6.
7. Cooksey RC, Crawford JT, JacobsWRJr et al. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother 1993; 37: 1348-52.
8. Arain TM, Resconi AE, Hickey MJ et al. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob Agents Chemother 1996; 40: 1536-41.
9. Deb DK, Srivastava KK, Srivastava R et al. Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem Biophys Res Commun 2000; 279: 457-61.
10. Andreu N, Fletcher T, Krishnan N et al. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 2012; 67: 404-14.
11. Heuts F, Carow B, Wigzell H et al. Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect 2009; 11: 1114-21.
12. Zhang T, Li S-Y, Converse PJ et al. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother 2011; 55: 56-61.
13. Andreu N, Zelmer A, Fletcher T et al. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 2010; 5: e10777.
14. Zhang T, Li S-Y, Nuermberger EL. Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One 2012; 7: e29774.
15. Springer B, Sander P, Sedlacek L et al. Instability and site-specific excision of integration-proficient mycobacteriophage L5 plasmids: development of stably maintained integrative vectors. Int J Med Microbiol 2001; 290: 669-75.
16. Fujii H, Noda K, Asami Y et al. Increase in bioluminescence intensity of firefly luciferase using genetic modification. Anal Biochem 2007; 366: 131-6.
17. Branchini BR, Ablamsky DM, Murtiashaw MH et al. Thermostable red and green light-producing firefly luciferase mutants for bioluminescent reporter applications. Anal Biochem 2007; 361: 253-62.
18. Barker LP, Brooks DM, Small PL. The identification of Mycobacterium marinum genes differentially expressed in macrophage phagosomes using promoter fusions to green fluorescent protein. Mol Microbiol 1998; 29: 1167-77.
19. Barker LP, Porcella SF, Wyatt RG et al. The Mycobacterium marinum G13 promoter is a strong sigma 70-like promoter that is expressed in Escherichia coli and mycobacteria species. FEMS Microbiol Lett 1999; 175: 79-85.
20. Rettig GR, McAnuffM, Liu D et al. Quantitative bioluminescence imaging of transgene expression in vivo. Anal Biochem 2006; 355: 90-4.
21. Lee KH, Byun SS, Paik JY et al. Cell uptake and tissue distribution of radioiodine labelled D-luciferin: implications for luciferase based gene imaging. Nucl Med Commun 2003; 24: 1003-9.
22. Baggett B, Roy R, Momen S et al. Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence. Mol Imaging 2004; 3: 324-32.
23. Rullas J, García JI, Beltrán M et al. Fast standardized therapeuticefficacy assay for drug discovery against tuberculosis. Antimicrob Agents Chemother 2010; 54: 2262-4.
24. Franzblau SG, DeGroote MA, Cho SH et al. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis 2012; 92: 453-88.
25. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J et al. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One 2010; 5: e9823.
26. Zelmer A, Carroll P, Andreu N et al. A new in vivo model to test antituberculosis drugs using fluorescence imaging. J Antimicrob Chemother 2012; 67: 1948-60.
27. Kong Y, Yao H, Ren H et al. Imaging tuberculosis with endogenous b-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci USA 2010; 107: 12239-44.